Bruins, Laura A.

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Van Wier, S., Chang, X.-B., Bjorklund, C. C., Fonseca, R., Bergsagel, P. L., et al. (2011) · Blood

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 607

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes

Kortüm, K. M., Mai, E. K., Hanafiah, N. H., Shi, C.-X., Zhu, Y.-X., Bruins, L., Barrio, S., Jedlowski, P., Merz, M., Xu, J., et al. (2016) · Blood

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 255

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma

Zhu, Y. X., Braggio, E., Shi, C.-X., Kortuem, K. M., Bruins, L. A., Schmidt, J. E., Chang, X.-B., Langlais, P., Luo, M., Jedlowski, P., et al. (2014) · Blood

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 213

The clinical significance of cereblon expression in multiple myeloma

Schuster, S. R., Kortuem, K. M., Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Ahmann, G., Kumar, S., Rajkumar, S. V., et al. (2014) · Leukemia Research

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 113

IKZF1/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma

Barrio, S., Munawar, U., Zhu, Y. X., Giesen, N., Shi, C.-X., Viá, M. D., Sanchez, R., Bruins, L., Demler, T., Müller, N., et al. (2020) · Haematologica

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 67